Compare Cigna Corp (CI) vs Ingersoll Rand (IR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs Ingersoll Rand — how do they compare? Cigna Corp trades at $281.62 (market cap $76.34B), while Ingersoll Rand trades at $71.57 (market cap $27.90B). The key difference: Cigna Corp is far larger — about 2.7× Ingersoll Rand's market cap, and Cigna Corp pays the higher dividend (2.16%). Which is the better fit depends on your goals.
| CI | IR | |
|---|---|---|
Market Cap | $76.34B | $27.90B |
Volume | 1,107,394 | 5,665,729 |
Sector | Health | Industrials |
52-Week High | $311.00 | $98.76 |
52-Week Low | $244.41 | $68.54 |
Typical Hold Time | 64 Days | — |
Enterprise Value | $101.05B | $31.56B |
Dividend Yield | 2.16% | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna Group (CI) trades at $289.53, up 3.12% today, reflecting strong momentum amid a bullish technical signal. The stock exhibits solid fundamentals with a P/E of 12 and consistent earnings beats in recent quarters, including Q2 2026 EPS of $7.78 versus $7.60 expected. Revenue growth is robust, climbing to $273.85B in 2025, while analyst sentiment is overwhelmingly positive with 28 buy ratings and a $331 consensus price target. Recent corporate news includes an upcoming Investor Day on September 30, 2026, highlighting strategic initiatives.
The outlook for CI remains favorable, supported by earnings growth, shareholder returns via dividends, and institutional accumulation. Key risks include rising medical costs and debt levels, but the company's competitive positioning and operational cash flow generation provide a buffer. The stock presents a value opportunity with upside to analyst targets, though investors should monitor expense trends and regulatory developments in the healthcare sector.
Ingersoll Rand (IR) trades at $71.91, down 1.4% today, amid a bearish technical signal. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.86 surpassing the $0.827 forecast. Revenue guidance for 2026 was raised to 4.5%-6.5% growth, though margins faced compression. The stock shows strong analyst support with a consensus price target of $95.33 and no sell ratings among 15 analysts.
The outlook is positive given earnings momentum and raised guidance, but high valuation (P/E 29.81) and technical bearishness pose near-term risks. Profitability improvements in 2026 and institutional accumulation offer upside, while margin pressures and economic sensitivity require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About Ingersoll Rand
Ingersoll Rand develops industrial technologies for creating and managing flow, pressure, and motion. Its portfolio includes compressors, pumps, vacuum systems, and other equipment used across industrial markets.
Read more on IR →
